Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Amlitelimab by Sanofi for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
Amlitelimab is under clinical development by Sanofi and currently in Phase III for Atopic Dermatitis (Atopic Eczema). According to GlobalData,...
Amlitelimab by Sanofi for Hidradenitis Suppurativa: Likelihood of Approval
Amlitelimab is under clinical development by Sanofi and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase II...
Amlitelimab by Sanofi for Asthma: Likelihood of Approval
Amlitelimab is under clinical development by Sanofi and currently in Phase II for Asthma. According to GlobalData, Phase II drugs...
Amlitelimab by Sanofi for Celiac Disease: Likelihood of Approval
Amlitelimab is under clinical development by Sanofi and currently in Phase II for Celiac Disease. According to GlobalData, Phase II...
Amlitelimab by Sanofi for Alopecia Areata: Likelihood of Approval
Amlitelimab is under clinical development by Sanofi and currently in Phase II for Alopecia Areata. According to GlobalData, Phase II...
Amlitelimab by Sanofi for Systemic Sclerosis (Scleroderma): Likelihood of Approval
Amlitelimab is under clinical development by Sanofi and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Sanofi's Amlitelimab?
Amlitelimab is a monoclonal antibody commercialized by Sanofi, with a leading Phase III program in Atopic Dermatitis (Atopic Eczema). According...
Risk adjusted net present value: What is the current valuation of Sanofi's Amlitelimab?
Amlitelimab is a monoclonal antibody commercialized by Sanofi, with a leading Phase III program in Atopic Dermatitis (Atopic Eczema). According...